Treatment with demethylating agent, 5-aza-2′-deoxycytidine enhances therapeutic HPV DNA vaccine potency

Vaccine

Volumn 27, Issue 32, 2009, Pages 4363-4369

  Lu, Dan ^a   Hoory, Talia ^a   Monie, Archana ^a   Wu, Annie ^a   Wang, Mei Cheng ^a   Hung, Chien Fu ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

5 Aza 2 deoxycytidine (DAC); Calreticulin (CRT); DNA vaccine; HPV 16 E7

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CALRETICULIN; DNA VACCINE; PROTEIN E7;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; VACCINATION;

ANIMALS; AZACITIDINE; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GENE EXPRESSION; HUMANS; MICE; PAPILLOMAVIRUS VACCINES; SURVIVAL ANALYSIS; VACCINES, DNA;

EID: 67649506210     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.02.041     Document Type: Article

References (29)

1. Donnelly J.J., Ulmer J.B., Shiver J.W., and Liu M.A. DNA vaccines. Annu Rev Immunol 15 (1997) 617-648
2. Gurunathan S., Klinman D.M., and Seder R.A. DNA vaccines: immunology, application, and optimization*. Annu Rev Immunol 18 (2000) 927-974
3. Hung C.F., and Wu T.C. Improving DNA vaccine potency via modification of professional antigen presenting cells. Curr Opin Mol Ther 5 1 (2003) 20-24
4. Tsen S.W., Paik A.H., Hung C.F., and Wu T.C. Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells. Expert Rev Vaccines 6 2 (2007) 227-239
5. Gelebart P., Opas M., and Michalak M. Calreticulin, a Ca2+-binding chaperone of the endoplasmic reticulum. Int J Biochem Cell Biol 37 2 (2005) 260-266
6. Bosch F.X., Lorincz A., Munoz N., Meijer C.J., and Shah K.V. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55 4 (2002) 244-265
7. Cheng W.F., Hung C.F., Chai C.Y., Hsu K.F., He L., Ling M., et al. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest 108 5 (2001) 669-678
8. Kim J.W., Hung C.F., Juang J., He L., Kim T.W., Armstrong D.K., et al. Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Ther 11 12 (2004) 1011-1018
9. Peng S., Tomson T.T., Trimble C., He L., Hung C.F., and Wu T.C. A combination of DNA vaccines targeting human papillomavirus type 16 E6 and E7 generates potent antitumor effects. Gene Ther 13 3 (2006) 257-265
10. Pamer E., and Cresswell P. Mechanisms of MHC class I-restricted antigen processing. Annu Rev Immunol 16 (1998) 323-358
11. Ochiai H., Harashima H., and Kamiya H. Intranuclear disposition of exogenous DNA in vivo: silencing, methylation and fragmentation. FEBS Lett 580 3 (2006) 918-922
12. Brooks A.R., Harkins R.N., Wang P., Qian H.S., Liu P., and Rubanyi G.M. Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle. J Gene Med 6 4 (2004) 395-404
13. Suzuki H., Gabrielson E., Chen W., Anbazhagan R., van Engeland M., Weijenberg M.P., et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 31 2 (2002) 141-149
14. Yu N., and Wang M. Anticancer drug discovery targeting DNA hypermethylation. Curr Med Chem 15 14 (2008) 1350-1375
15. Arai M., Imazeki F., Sakai Y., Mikata R., Tada M., Seki N., et al. Analysis of the methylation status of genes up-regulated by the demethylating agent, 5-aza-2′-deoxycytidine, in esophageal squamous cell carcinoma. Oncol Rep 20 2 (2008) 405-412
16. Appleton K., Mackay H.J., Judson I., Plumb J.A., McCormick C., Strathdee G., et al. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol 25 29 (2007) 4603-4609
17. Yoo C.B., Jeong S., Egger G., Liang G., Phiasivongsa P., Tang C., et al. Delivery of 5-aza-2′-deoxycytidine to cells using oligodeoxynucleotides. Cancer Res 67 13 (2007) 6400-6408
18. Lin K.Y., Guarnieri F.G., Staveley-O'Carroll K.F., Levitsky H.I., August J.T., Pardoll D.M., et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56 1 (1996) 21-26
19. Chen C.H., Wang T.L., Hung C.F., Yang Y., Young R.A., Pardoll D.M., et al. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 60 4 (2000) 1035-1042
20. Kim D., Gambhira R., Karanam B., Monie A., Hung C.F., Roden R., et al. Generation and characterization of a preventive and therapeutic HPV DNA vaccine. Vaccine 26 3 (2008) 351-360
21. Choi K.H., Basma H., Singh J., and Cheng P.W. Activation of CMV promoter-controlled glycosyltransferase and beta-galactosidase glycogenes by butyrate, tricostatin A, and 5-aza-2′-deoxycytidine. Glycoconj J 22 1-2 (2005) 63-69
22. Grassi G., Maccaroni P., Meyer R., Kaiser H., D'Ambrosio E., Pascale E., et al. Inhibitors of DNA methylation and histone deacetylation activate cytomegalovirus promoter-controlled reporter gene expression in human glioblastoma cell line U87. Carcinogenesis 24 10 (2003) 1625-1635
23. Trimble C.L., Peng S., Kos F., Gravitt P., Viscidi R., Sugar E., et al. A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res 15 1 (2009) 361-367
24. Trimble C., Lin C.T., Hung C.F., Pai S., Juang J., He L., et al. Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine 21 25-26 (2003) 4036-4042
25. Tseng C.W., Monie A., Trimble C., Alvarez R.D., Huh W.K., Buchsbaum D.J., et al. Combination of treatment with death receptor 5-specific antibody with therapeutic HPV DNA vaccination generates enhanced therapeutic anti-tumor effects. Vaccine 26 34 (2008) 4314-4319
26. Tseng C.W., Monie A., Wu C.Y., Huang B., Wang M.C., Hung C.F., et al. Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination. J Mol Med (Berlin, Germany) 86 8 (2008) 899-908
27. Bae S.H., Park Y.J., Park J.B., Choi Y.S., Kim M.S., and Sin J.I. Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: causal involvement of increased sensitivity of cisplatin-treated tumors to CTL-mediated killing in therapeutic synergy. Clin Cancer Res 13 1 (2007) 341-349
28. Tseng C.W., Hung C.F., Alvarez R.D., Trimble C., Huh W.K., Kim D., et al. Pretreatment with cisplatin enhances E7-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination. Clin Cancer Res 14 10 (2008) 3185-3192
29. Lemaire M., Chabot G.G., Raynal N.J., Momparler L.F., Hurtubise A., Bernstein M.L., et al. Importance of dose-schedule of 5-aza-2′-deoxycytidine for epigenetic therapy of cancer. BMC Cancer 8 1 (2008) 128